{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:33:28Z","timestamp":1758267208074,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-016-2106-x","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T04:46:47Z","timestamp":1483764407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Jim","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Giostra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Pascasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluis","family":"Castells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roelien","family":"Postema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinira","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner C.","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,7]]},"reference":[{"key":"2106_CR1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124\u201335.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2106_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34\u201359.","journal-title":"J Viral Hepat"},{"key":"2106_CR3","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"H Razavi","year":"2013","unstructured":"Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164\u201370.","journal-title":"Hepatology"},{"key":"2106_CR4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","volume":"55","author":"EASL","year":"2011","unstructured":"EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245\u201364.","journal-title":"J Hepatol"},{"key":"2106_CR5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1478-3231.2009.02188.x","volume":"30","author":"N Antaki","year":"2010","unstructured":"Antaki N, Craxi A, Kamal S, Moucari R, Van der MS, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342\u201355.","journal-title":"Liver Int"},{"key":"2106_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/apt.13264","volume":"42","author":"C Bunchorntavakul","year":"2015","unstructured":"Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015;42:258\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"2106_CR7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s40267-015-0272-3","volume":"32","author":"PL McCormack","year":"2016","unstructured":"McCormack PL, Lyseng-Williamson KA. Daclatasvir in hepatitic C virus infection: a guide to its use in the EU. Drugs Ther Perspect. 2016;32:42\u20139.","journal-title":"Drugs Ther Perspect"},{"key":"2106_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u201321.","journal-title":"N Engl J Med"},{"key":"2106_CR9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2014.04.042","volume":"61","author":"T Asselah","year":"2014","unstructured":"Asselah T. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol. 2014;61:435\u20138.","journal-title":"J Hepatol"},{"key":"2106_CR10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1586\/17474124.2016.1143775","volume":"10","author":"CS Hsu","year":"2016","unstructured":"Hsu CS, Kao JH. Management of hepatitis C patients with decompensated liver disease. Expert Rev Gastroenterol Hepatol. 2016;10:679\u201388.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"2106_CR11","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2016. http:\/\/www.hcvguidelines.org\/full-report\/unique-patient-populations-patients-decompensated-cirrhosis . Accessed 11 Nov 2016."},{"key":"2106_CR12","unstructured":"EASL. Recommendations on treatment of hepatitis C 2016. 2016 http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/easl-recommendations-on-treatment-of-hepatitis-c-2016 . Accessed 11 Nov 2016."},{"key":"2106_CR13","doi-asserted-by":"crossref","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. third. Bayesian data analysis. Boca Raton: CRC Press; 2013.","DOI":"10.1201\/b16018"},{"key":"2106_CR14","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1002\/sim.2788","volume":"26","author":"S Greenland","year":"2007","unstructured":"Greenland S. Prior data for non-normal priors. Stat Med. 2007;26:3578\u201390.","journal-title":"Stat Med"},{"key":"2106_CR15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ije\/dyi312","volume":"35","author":"S Greenland","year":"2006","unstructured":"Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol. 2006;35:765\u201375.","journal-title":"Int J Epidemiol"},{"key":"2106_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/ije\/dyl289","volume":"36","author":"S Greenland","year":"2007","unstructured":"Greenland S. Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol. 2007;36:195\u2013202.","journal-title":"Int J Epidemiol"},{"key":"2106_CR17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1468-1293.2010.00885.x","volume":"12","author":"J Young","year":"2011","unstructured":"Young J, Scherrer AU, Gunthard HF, Opravil M, Yerly S, Boni J, et al. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Med. 2011;12:299\u2013307.","journal-title":"HIV Med"},{"key":"2106_CR18","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/S0140-6736(15)60605-5","volume":"385","author":"H Wedemeyer","year":"2015","unstructured":"Wedemeyer H. Towards interferon-free treatment for all HCV genotypes. Lancet. 2015;385:2443\u20135.","journal-title":"Lancet"},{"key":"2106_CR19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2015.09.009","volume":"64","author":"C Hezode","year":"2016","unstructured":"Hezode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: the role of ribavirin. J Hepatol. 2016;64:215\u201325.","journal-title":"J Hepatol"},{"key":"2106_CR20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","volume":"64","author":"GR Foster","year":"2016","unstructured":"Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224\u201331.","journal-title":"J Hepatol."},{"key":"2106_CR21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized Phase III study (ALLY-3+). Hepatology. 2016; 63:1430\u201341.","journal-title":"Hepatology."},{"key":"2106_CR22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714\u201325.","journal-title":"N Engl J Med"},{"key":"2106_CR23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127\u201335.","journal-title":"Hepatology"},{"key":"2106_CR24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"F Poordad","year":"2016","unstructured":"Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493\u2013505.","journal-title":"Hepatology"},{"key":"2106_CR25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.05.039","volume":"65","author":"A Coilly","year":"2016","unstructured":"Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. J Hepatol. 2016;65:711\u20138.","journal-title":"J Hepatol"},{"key":"2106_CR26","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","volume":"65","author":"TM Welzel","year":"2016","unstructured":"Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861\u201370.","journal-title":"Gut"},{"key":"2106_CR27","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0168-8278(15)30159-8","volume":"62","author":"C Hezode","year":"2015","unstructured":"Hezode C, De Ledinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program (abstract LP05). J Hepatol. 2015;62:S265\u20136.","journal-title":"J Hepatol"},{"key":"2106_CR28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4254\/wjh.v7.i8.1133","volume":"7","author":"S Nakamoto","year":"2015","unstructured":"Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol. 2015;7:1133\u201341.","journal-title":"World J Hepatol"},{"issue":"Suppl 1","key":"2106_CR29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/liv.12391","volume":"34","author":"V Boccaccio","year":"2014","unstructured":"Boccaccio V, Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals. Liver Int. 2014;34 Suppl 1:38\u201345.","journal-title":"Liver Int"},{"key":"2106_CR30","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2014.07.020","volume":"61","author":"M Gambato","year":"2014","unstructured":"Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61:S120\u201331.","journal-title":"J Hepatol"},{"key":"2106_CR31","unstructured":"CIOMS. International ethical guidelines for epidemiological studies. 2009. http:\/\/www.cioms.ch\/index.php\/publications\/printablev3\/541\/showCategory\/65\/bioethics-and-health-policy-guidelines-and-other-normative-documents . Accessed 9 Dec 2016."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-2106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T17:25:21Z","timestamp":1601313921000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-2106-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-2106-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2017,1,7]]},"article-number":"45"}}